ABBV-399 showed promising efficacy against nonsquamous NSCLC in a phase II study, with an ORR of 35.1% in patients with c-MET-positive, wild-type EGFR nonsquamous NSCLC, 53.8% in the high-expression group and 25% in the moderate expression group; however, ABBV-399 had only limited efficacy in the patient groups with EGFR mutation and squamous NSCLC [264]. The gene discussed is MET; the disease is non-small cell lung carcinoma.